<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Immune Based Ther Vaccines</journal-id><journal-title>Journal of Immune Based Therapies and Vaccines</journal-title><issn pub-type="epub">1476-8518</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16734912</article-id><article-id pub-id-type="pmc">1540413</article-id><article-id pub-id-type="publisher-id">1476-8518-4-3</article-id><article-id pub-id-type="doi">10.1186/1476-8518-4-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Levamizole enhances immune responsiveness to intra-dermal and intra-muscular hepatitis B vaccination in chronic hemodialysis patients</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Argani</surname><given-names>Hassan</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>hassanargani@hotmail.com</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Akhtarishojaie</surname><given-names>Ebrahim</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>akhtari20@yahoo.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Division of nephrology, Modarres hospital, Shahid beheshti university of medical sciences, Tehran, Iran</aff><aff id="I2"><label>2</label>Drug applied research center, Tabriz university of medical sciences, Tabriz, Iran</aff><aff id="I3"><label>3</label>Drug applied research center, Tabriz university of medical sciences, Tabriz, Iran</aff><pub-date pub-type="collection"><year>2006</year></pub-date><pub-date pub-type="epub"><day>30</day><month>5</month><year>2006</year></pub-date><volume>4</volume><fpage>3</fpage><lpage>3</lpage><ext-link ext-link-type="uri" xlink:href="http://www.jibtherapies.com/content/4/1/3"></ext-link><history><date date-type="received"><day>25</day><month>11</month><year>2005</year></date><date date-type="accepted"><day>30</day><month>5</month><year>2006</year></date></history><permissions><copyright-statement>Copyright © 2006 Hassan and Ebrahim; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>Hassan and Ebrahim; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"></ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title><offsets xml_i="3019" xml_f="3029" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="3040" xml_f="3116" txt_i="22" txt_f="98">Hemodialysis patient are at high risk for hepatitis B virus (HBV) infection.</offsets></p><p><offsets xml_i="3123" xml_f="3467" txt_i="99" txt_f="443">Although preventive vaccination is done routinely, the response to vaccination is low in this patient population. The aim of this study was to evaluate the effect of Levamizol, an enhancer of the immune responsiveness, on different routs of vaccination, i.e., intradermal (ID) versus intramuscular (IM), in stable chronic hemodialysis patients.</offsets></p></sec><sec sec-type="materials|methods"><title><offsets xml_i="3518" xml_f="3539" txt_i="445" txt_f="466">Materials and methods</offsets></title><p><offsets xml_i="3550" xml_f="3978" txt_i="467" txt_f="895">Forty four chronic heamodialyses patient were divided into four equal groups. The first group was received 40 μg HB vaccine intramuscularly. The second group was received 20 μg HB vaccine intradermally. The third and the fourth group received 20 μg vaccine IM or ID, respectively, in three doses plus oral Levamisole (100 mg for 12 day). After one and six months from the last dose of vaccine, HBs antibody titers were measured.</offsets></p></sec><sec><title><offsets xml_i="4000" xml_f="4007" txt_i="897" txt_f="904">Results</offsets></title><p><offsets xml_i="4018" xml_f="4332" txt_i="905" txt_f="1213">The response rate to vaccine (HBs Antibody&gt;10 μg/L) in the routine IM HB vaccination was low (60%). It increased to 70% with ID route. Levamisole significantly raised the response rate to 90% (P &lt; 0.01). Also in the Levamisole groups protective HB antibody titers were maintained until the end of six months.</offsets></p><p><offsets xml_i="4339" xml_f="4474" txt_i="1214" txt_f="1349">We conclude that HD patients must be vaccinated by ID route and addition of Levamisole. Levamisole also increases antibody maintenance.</offsets></p></sec></abstract></article-meta></front><body><sec><title><offsets xml_i="4536" xml_f="4546" txt_i="1358" txt_f="1368">Background</offsets></title><p><offsets xml_i="4557" xml_f="4671" txt_i="1369" txt_f="1483">Hepatitis B virus (HBV) infection is a worldwide health problem with increased incidence in developing countries [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="4702" xml_f="4703" txt_i="1483" txt_f="1484">1</offsets></xref><offsets xml_i="4710" xml_f="4711" txt_i="1484" txt_f="1485">-</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="4742" xml_f="4743" txt_i="1485" txt_f="1486">4</offsets></xref><offsets xml_i="4750" xml_f="4752" txt_i="1486" txt_f="1488">].</offsets></p><p><offsets xml_i="4759" xml_f="4997" txt_i="1489" txt_f="1727">Despite improvements in infection control guidelines and dialysis techniques, patients with chronic renal failure (CRF) are at increased risk for HBV infection because of their suppressed immunity and frequent exposure to blood products [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="5028" xml_f="5029" txt_i="1727" txt_f="1728">5</offsets></xref><offsets xml_i="5036" xml_f="5037" txt_i="1728" txt_f="1729">-</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="5068" xml_f="5069" txt_i="1729" txt_f="1730">8</offsets></xref><offsets xml_i="5076" xml_f="5155" txt_i="1730" txt_f="1809">]. Therefore, it is suggested that all CRF patients be vaccinated against HBV [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="5186" xml_f="5187" txt_i="1809" txt_f="1810">9</offsets></xref><offsets xml_i="5194" xml_f="5195" txt_i="1810" txt_f="1811">-</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="5227" xml_f="5229" txt_i="1811" txt_f="1813">13</offsets></xref><offsets xml_i="5236" xml_f="5427" txt_i="1813" txt_f="2004">]. With the routine use of hepatitis B vaccination the incidence of hepatitis B infection has been reduced significantly from 30% in 1976 to 0.05% in 1997 among patients on chronic dialysis [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="5459" xml_f="5461" txt_i="2004" txt_f="2006">13</offsets></xref><offsets xml_i="5468" xml_f="5469" txt_i="2006" txt_f="2007">-</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="5501" xml_f="5503" txt_i="2007" txt_f="2009">15</offsets></xref><offsets xml_i="5510" xml_f="5512" txt_i="2009" txt_f="2011">].</offsets></p><p><offsets xml_i="5519" xml_f="5851" txt_i="2012" txt_f="2344">The increased susceptibility to infections among these patients is due to immunodeficiency status manifested by abnormal phagocytosis, T and B-lymphocyte abnormalities, and impaired responses to T cell dependent pathogens such as hepatitis B virus. Therefore, these patients are predisposed to develop chronic hepatitis infections [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="5883" xml_f="5885" txt_i="2344" txt_f="2346">16</offsets></xref><offsets xml_i="5892" xml_f="5893" txt_i="2346" txt_f="2347">-</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="5925" xml_f="5927" txt_i="2347" txt_f="2349">19</offsets></xref><offsets xml_i="5934" xml_f="5936" txt_i="2349" txt_f="2351">].</offsets></p><p><offsets xml_i="5943" xml_f="6200" txt_i="2352" txt_f="2609">Although preventive vaccination is done routinely in patients with end stage renal failure (ESRF), antibody response to vaccination is suppressed and its level rapidly declines among patients on chronic dialysis due to the decreased immunological response [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="6232" xml_f="6234" txt_i="2609" txt_f="2611">15</offsets></xref><offsets xml_i="6241" xml_f="6242" txt_i="2611" txt_f="2612">-</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="6274" xml_f="6276" txt_i="2612" txt_f="2614">17</offsets></xref><offsets xml_i="6283" xml_f="6285" txt_i="2614" txt_f="2616">].</offsets></p><p><offsets xml_i="6292" xml_f="6505" txt_i="2617" txt_f="2830">Levamisole is an anti helminthic drug which has a property to stimulate T cell activity and enhance B lymphocyte function. Thus, it can be used for up-regulation of defective immune function in patients with CRF [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="6536" xml_f="6537" txt_i="2830" txt_f="2831">7</offsets></xref><offsets xml_i="6544" xml_f="6894" txt_i="2831" txt_f="3181">]. Vaccination via the intradermal route (ID) is considered an alternative method of vaccination which could be more effective than the conventional intramuscular (IM) rout. It is effective in inducing HBs antibody production by increasing T and B lymphocyte responsiveness, probably through facilitating a greater contact with the antigen overtime [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="6926" xml_f="6928" txt_i="3181" txt_f="3183">20</offsets></xref><offsets xml_i="6935" xml_f="6936" txt_i="3183" txt_f="3184">-</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="6968" xml_f="6970" txt_i="3184" txt_f="3186">22</offsets></xref><offsets xml_i="6977" xml_f="6979" txt_i="3186" txt_f="3188">].</offsets></p><p><offsets xml_i="6986" xml_f="7250" txt_i="3189" txt_f="3453">Recent studies have shown that ID administered HB vaccine is an effective rout to induce anti-HBs Ag serum antibodies. Furthermore, the ID administration of HB vaccine has higher clinical efficacy to induce humoral immune responses than the conventional IM route [</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="7282" xml_f="7284" txt_i="3453" txt_f="3455">23</offsets></xref><offsets xml_i="7291" xml_f="7533" txt_i="3455" txt_f="3697">]. The aim of this study was to investigate the effectiveness of Levamizol in enhancing the immune response to different routs of vaccination in hemodialysis patients, as well as the effect on maintenance of the protective HBs antibody titer.</offsets></p></sec><sec><title><offsets xml_i="7555" xml_f="7574" txt_i="3699" txt_f="3718">Patients and method</offsets></title><p><offsets xml_i="7585" xml_f="8055" txt_i="3719" txt_f="4189">In our hemodialysis center from March 2002 to February 2003, 128 stable patients end stage renal disease were dialyzed 3 times per week by low flux cellulosynthetic membrane. After excluding of the patients with history of HB vaccination, current therapy with any immunosuppressive drugs, malnutrition, recent hospitalization (during the last 3 months), and positive HBs antibody and/or Hbs antigen, 44 stable chronic hemodialysis patients recruited to the study (Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="8087" xml_f="8088" txt_i="4189" txt_f="4190">1</offsets></xref><offsets xml_i="8095" xml_f="8240" txt_i="4190" txt_f="4335">). None of the patients had significant co-morbid conditions such as congestive heart failure, uncontrolled diabetes mellitus or liver cirrhosis.</offsets></p><table-wrap position="float" id="T1"><label><offsets xml_i="8288" xml_f="8295" txt_i="4336" txt_f="4343">Table 1</offsets></label><caption><p><offsets xml_i="8315" xml_f="8377" txt_i="4343" txt_f="4405">Demographic characteristics of the patients in the four groups</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center"><offsets xml_i="8467" xml_f="8478" txt_i="4407" txt_f="4418">Age (years)</offsets></td><td align="center"><offsets xml_i="8502" xml_f="8522" txt_i="4419" txt_f="4439">Gender (male/female)</offsets></td><td align="center"><offsets xml_i="8546" xml_f="8572" txt_i="4440" txt_f="4466">Underlying disease (cases)</offsets></td><td align="center"><offsets xml_i="8596" xml_f="8597" txt_i="4467" txt_f="4468">p</offsets></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="8643" xml_f="8650" txt_i="4469" txt_f="4476">Group A</offsets></td><td align="center"><offsets xml_i="8674" xml_f="8682" txt_i="4477" txt_f="4485">47 ± 9.6</offsets></td><td align="center"><offsets xml_i="8706" xml_f="8709" txt_i="4486" txt_f="4489">7/4</offsets></td><td align="left"><offsets xml_i="8731" xml_f="8769" txt_i="4490" txt_f="4528">DM:(3), GN:(2), HTN:(2), UN:(3), O:(1)</offsets></td><td align="center"><offsets xml_i="8793" xml_f="8796" txt_i="4529" txt_f="4532">ns.</offsets></td></tr><tr><td align="left"><offsets xml_i="8827" xml_f="8834" txt_i="4533" txt_f="4540">Group B</offsets></td><td align="center"><offsets xml_i="8858" xml_f="8866" txt_i="4541" txt_f="4549">45 ± 9.1</offsets></td><td align="center"><offsets xml_i="8890" xml_f="8893" txt_i="4550" txt_f="4553">6/5</offsets></td><td align="left"><offsets xml_i="8915" xml_f="8953" txt_i="4554" txt_f="4592">DM:(3), GN:(2), HTN:(2), UN:(3), O:(1)</offsets></td><td align="center"><offsets xml_i="8977" xml_f="8980" txt_i="4593" txt_f="4596">ns.</offsets></td></tr><tr><td align="left"><offsets xml_i="9011" xml_f="9018" txt_i="4597" txt_f="4604">Group C</offsets></td><td align="center"><offsets xml_i="9042" xml_f="9050" txt_i="4605" txt_f="4613">48 ± 8.3</offsets></td><td align="center"><offsets xml_i="9074" xml_f="9077" txt_i="4614" txt_f="4617">6/5</offsets></td><td align="left"><offsets xml_i="9099" xml_f="9137" txt_i="4618" txt_f="4656">DM:(3), GN:(2), HTN:(2), UN:(3), O:(1)</offsets></td><td align="center"><offsets xml_i="9161" xml_f="9164" txt_i="4657" txt_f="4660">ns.</offsets></td></tr><tr><td align="left"><offsets xml_i="9195" xml_f="9202" txt_i="4661" txt_f="4668">Group D</offsets></td><td align="center"><offsets xml_i="9226" xml_f="9234" txt_i="4669" txt_f="4677">41 ± 7.2</offsets></td><td align="center"><offsets xml_i="9258" xml_f="9261" txt_i="4678" txt_f="4681">6/5</offsets></td><td align="left"><offsets xml_i="9283" xml_f="9321" txt_i="4682" txt_f="4720">DM:(3), GN:(2), HTN:(2), UN:(3), O:(1)</offsets></td><td align="center"><offsets xml_i="9345" xml_f="9348" txt_i="4721" txt_f="4724">ns.</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="9394" xml_f="9747" txt_i="4725" txt_f="5078">It is non significant (ns) differences of age, gender and causes of renal failure in the four groups; DM: Diabetes Mellitus, GN: Glomerulonephritis, HTN: Hypertension, UN: Unknown causes, O: Other causes (includes: Alport syndrome in 1 case, Autosomal dominant polycystic disease in 1 case, Nephrolithiasis in 1 case and obstructive uropathy in 1 case).</offsets></p></table-wrap-foot></table-wrap><p><offsets xml_i="9785" xml_f="10006" txt_i="5079" txt_f="5300">After obtaining of informed consent, 20 or 40 microgram of recombinant human HB vaccine (from Heber Biotec, S.A., Havana, Cuba, brochure no. 1-8-0090-LI) was received to the patients three times; at the months 0, 1 and 6.</offsets></p><p><offsets xml_i="10013" xml_f="10108" txt_i="5301" txt_f="5393">Each ml of the vaccine contained 20 microgram of surface antigen protein (with &gt;95% purity).</offsets></p><p><offsets xml_i="10115" xml_f="10170" txt_i="5394" txt_f="5449">The patients randomly divided in to four groups (Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="10202" xml_f="10203" txt_i="5449" txt_f="5450">1</offsets></xref><offsets xml_i="10210" xml_f="10212" txt_i="5450" txt_f="5452">):</offsets></p><p><offsets xml_i="10219" xml_f="10361" txt_i="5453" txt_f="5595">1-Group A: 11 patients received 2 ml (40 μg) of the vaccine, which was administered as a single intramuscular injection in the deltoid muscle.</offsets></p><p><offsets xml_i="10368" xml_f="10481" txt_i="5596" txt_f="5709">2- Group B: 11 patients received 1 ml (20 μg) of the vaccine intradermally in the ventral surface of the forearm.</offsets></p><p><offsets xml_i="10488" xml_f="10691" txt_i="5710" txt_f="5913">3- Group C: 11 patients received 1 ml (20 μg) of HB vaccine intramuscularly, plus 100 mg Levamisole per day for duration of 12 days, from 6 days before of vaccination until 6 days after each vaccination.</offsets></p><p><offsets xml_i="10698" xml_f="10887" txt_i="5914" txt_f="6103">4- Group D: 11 patients received 1 ml (20 μg) of the vaccine intradermally, plus 100 mg Levamisole per day for 12 day, from 6 days before of vaccination until 6 days after each vaccination.</offsets></p><p><offsets xml_i="10894" xml_f="11008" txt_i="6104" txt_f="6218">Demographic characteristics and the etiology of renal failure distributed uniformly in the four groups (Tabale-1).</offsets></p><p><offsets xml_i="11015" xml_f="11164" txt_i="6219" txt_f="6368">One and six months after the last dose of vaccination protocol HBs antibody titers were measured by ELISA method (DiaPlus Inc., Lot:8-112904, Italy).</offsets></p><p><offsets xml_i="11171" xml_f="11316" txt_i="6369" txt_f="6514">HBs antibody titer more than10 IU was considered positive and the titer more than 100 IU was considered good responders to vaccination protocol [</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="11348" xml_f="11350" txt_i="6514" txt_f="6516">24</offsets></xref><offsets xml_i="11357" xml_f="11358" txt_i="6516" txt_f="6517">,</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="11390" xml_f="11392" txt_i="6517" txt_f="6519">25</offsets></xref><offsets xml_i="11399" xml_f="11401" txt_i="6519" txt_f="6521">].</offsets></p><p><offsets xml_i="11408" xml_f="11471" txt_i="6522" txt_f="6585">The antibody responses in the 4 groups were compared by using X</offsets><sup><offsets xml_i="11476" xml_f="11478" txt_i="6585" txt_f="6587">2 </offsets></sup><offsets xml_i="11484" xml_f="11501" txt_i="6587" txt_f="6604">and Mann-Withney </offsets><italic><offsets xml_i="11509" xml_f="11511" txt_i="6604" txt_f="6606">U </offsets></italic><offsets xml_i="11520" xml_f="11670" txt_i="6606" txt_f="6753">test in Statistical Package of Social Science (SPSS) version 12 (licensed to university of Greenwich at 2003). P &lt; 0.05 was considered significant.</offsets></p></sec><sec><title><offsets xml_i="11692" xml_f="11699" txt_i="6755" txt_f="6762">Results</offsets></title><p><offsets xml_i="11710" xml_f="11992" txt_i="6763" txt_f="7045">In the 44 stable patients male to female ratio was 25 to 19 with the mean ( ± SD) age of 45 ± 8.6 years. Three of the 44 subjects were excluded due to death (1 case in group A) or renal transplantation (2 cases; one case in group B and the other in group C) during the study period.</offsets></p><p><offsets xml_i="11999" xml_f="12481" txt_i="7046" txt_f="7528">HB antibody titer in the group A was significantly lower than group B (28.9 ± 7 IU/L vs. 121.1 ± 82.3 IU/L, p = 0.04). Although the percent of seroconversion rate was lower in the group A than the group B (60% vs. 70%), it was not significant statistically. The antibody titers in groups C and D (IM and ID routs with using of Levamisole) were 541.1 ± 494.4 IU/L and 297.2 ± 9 IU/L (p = 0.6), respectively. The seroconversion rate, also, was similar in the both groups (90%) (Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="12513" xml_f="12514" txt_i="7528" txt_f="7529">2</offsets></xref><offsets xml_i="12521" xml_f="13067" txt_i="7529" txt_f="8075">). Thus, addition of Levamizol to intramuscular and intradermal vaccinations increased the antibody titers, 514.2 IU/L (p = 0.001) and 176.1 IU/L (p = 0.01), respectively. Evaluation of antibody titers 6 months after the last dose of vaccination showed that antibody concentration declined in all of the four groups, but this decrement was attenuated in the C group (IM+ Levamisole) and D group (ID+ Levamisole). Antibody titers in the A, B and C groups approximately were halved at the end of six months but it decreased only 30% in the D group.</offsets></p><table-wrap position="float" id="T2"><label><offsets xml_i="13115" xml_f="13122" txt_i="8076" txt_f="8083">Table 2</offsets></label><caption><p><offsets xml_i="13142" xml_f="13202" txt_i="8083" txt_f="8143">Hepatitis B antibody titers based on the rout of vaccination</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><offsets xml_i="13281" xml_f="13298" txt_i="8144" txt_f="8161">HB vaccine groups</offsets></td><td align="center"><offsets xml_i="13322" xml_f="13384" txt_i="8162" txt_f="8224">positive seroconversion rate after 1 month (antibody titer/IU)</offsets></td><td align="center"><offsets xml_i="13408" xml_f="13471" txt_i="8225" txt_f="8288">positive seroconversion rate after 6 months (antibody titer/IU)</offsets></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="13517" xml_f="13577" txt_i="8289" txt_f="8349">Group A (intra-muscular route by 40 microgram vaccine alone)</offsets></td><td align="center"><offsets xml_i="13601" xml_f="13625" txt_i="8350" txt_f="8374">60% (28.9 ± 7) *P = 0.04</offsets></td><td align="center"><offsets xml_i="13649" xml_f="13663" txt_i="8375" txt_f="8389">20% (16.7 ± 4)</offsets></td></tr><tr><td align="left"><offsets xml_i="13694" xml_f="13752" txt_i="8390" txt_f="8448">Group B (intra-dermal route by 20 microgram vaccine alone)</offsets></td><td align="center"><offsets xml_i="13776" xml_f="13805" txt_i="8449" txt_f="8478">70% (121.1 ± 82.3) #p = 0.005</offsets></td><td align="center"><offsets xml_i="13829" xml_f="13841" txt_i="8479" txt_f="8491">60% (58 ± 7)</offsets></td></tr><tr><td align="left"><offsets xml_i="13872" xml_f="13942" txt_i="8492" txt_f="8562">Group C (intra-muscular route by 20 microgram vaccine plus Levamisole)</offsets></td><td align="center"><offsets xml_i="13966" xml_f="13996" txt_i="8563" txt_f="8593">90% (543.1 ± 494.4) §p = 0.008</offsets></td><td align="center"><offsets xml_i="14020" xml_f="14033" txt_i="8594" txt_f="8607">80% (304 ± 7)</offsets></td></tr><tr><td align="left"><offsets xml_i="14064" xml_f="14132" txt_i="8608" txt_f="8676">Group D (intra-dermal route by 20 microgram vaccine plus Levamisole)</offsets></td><td align="center"><offsets xml_i="14156" xml_f="14181" txt_i="8677" txt_f="8702">90% (297.2 ± 90) €p = 0.6</offsets></td><td align="center"><offsets xml_i="14205" xml_f="14219" txt_i="8703" txt_f="8717">80% (209 ± 46)</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="14265" xml_f="14484" txt_i="8718" txt_f="8937">Seroconversion rate percent (when Ab titer was more than10 IU/L) and HB antibody titers (IU/L) one month and six months after different routs of vaccination. *Denotes comparison of antibody titer between groups A and B.</offsets></p><p><offsets xml_i="14491" xml_f="14553" txt_i="8938" txt_f="9000"># Denotes comparison of antibody titer between groups B and D.</offsets></p><p><offsets xml_i="14560" xml_f="14621" txt_i="9001" txt_f="9062">§Denotes comparison of antibody titer between groups A and C.</offsets></p><p><offsets xml_i="14628" xml_f="14690" txt_i="9063" txt_f="9125">€ Denotes comparison of antibody titer between groups C and D.</offsets></p></table-wrap-foot></table-wrap><p><offsets xml_i="14728" xml_f="15076" txt_i="9126" txt_f="9474">Aside of the higher HB antibody titer in the C and D groups, percentage of patients who retained HB antibody titer as protective level was higher after six months of follow up; i.e. protective antibody level persisted in 80% of patients in the latter two groups, vs. 60% of patients in the B group and only in 20% of patients in the A group (Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="15108" xml_f="15109" txt_i="9474" txt_f="9475">2</offsets></xref><offsets xml_i="15116" xml_f="15118" txt_i="9475" txt_f="9477">).</offsets></p><p><offsets xml_i="15125" xml_f="15586" txt_i="9478" txt_f="9939">Although mild localized pruritus or pain was explained by all of the patients in the B and D groups due to one ml of intradermal vaccination, any major side effect was not reported. Only one patient found mild generalized pruritus and another patient reported mild abdominal pain during the first week of Levamisole consumption, although both of the symptoms were relived by continuing of the drug and did not relapse at the succeeding courses of Levamisole in.</offsets></p></sec><sec><title><offsets xml_i="15608" xml_f="15618" txt_i="9941" txt_f="9951">Discussion</offsets></title><p><offsets xml_i="15629" xml_f="16447" txt_i="9952" txt_f="10770">In our hemodialysis patients, antibody response (antibody titer more than 10 IU/L) to routine IM vaccination of hepatitis B was low (60%) after one month, but it increased to 70% with ID route. The response rate to both IM and ID routs of vaccination increased significantly up to 90% at the end of one month with presence of Levamisole. Addition of Levamisole could extend the protective level of HB antibody titer and also the percentage of responders at least until six months. By adding of Levamisole 80% of the patients found sustained protective antibody level after six months. Although the antibody titer secondary to vaccination in C group (IM rout vaccination plus Levamisole) was higher than D group (ID rout vaccination plus Levamisole) at this time, the difference did not reach significant statistically.</offsets></p><p><offsets xml_i="16454" xml_f="16616" txt_i="10771" txt_f="10933">We suggest that hemodialysis patients vaccinated via the ID route would be better respond than the conventional IM rout, which also suggested by Theresa in 1998 [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="16647" xml_f="16648" txt_i="10933" txt_f="10934">6</offsets></xref><offsets xml_i="16655" xml_f="16678" txt_i="10934" txt_f="10957">], Pyone Keyi in 2002 [</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="16710" xml_f="16712" txt_i="10957" txt_f="10959">21</offsets></xref><offsets xml_i="16719" xml_f="16741" txt_i="10959" txt_f="10981">] and Rangle in 2000 [</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="16772" xml_f="16773" txt_i="10981" txt_f="10982">4</offsets></xref><offsets xml_i="16780" xml_f="16782" txt_i="10982" txt_f="10984">].</offsets></p><p><offsets xml_i="16789" xml_f="17036" txt_i="10985" txt_f="11232">Addition of Levamisole to vaccination protocol would further enhance the immunological response. The difference between the two routes of injection and with or without taking of Levamisole supplement reached highly statistical significance (Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="17068" xml_f="17069" txt_i="11232" txt_f="11233">2</offsets></xref><offsets xml_i="17076" xml_f="17078" txt_i="11233" txt_f="11235">).</offsets></p><p><offsets xml_i="17085" xml_f="17140" txt_i="11236" txt_f="11291">Our results further confirms the report of Ayli et al [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="17171" xml_f="17172" txt_i="11291" txt_f="11292">7</offsets></xref><offsets xml_i="17179" xml_f="17322" txt_i="11292" txt_f="11435">], which showed that Levamisole increases both serum antibody conversion rate and the duration that the antibody titer is maintained. Kayatas [</offsets><xref ref-type="bibr" rid="B26"><offsets xml_i="17354" xml_f="17356" txt_i="11435" txt_f="11437">26</offsets></xref><offsets xml_i="17363" xml_f="17918" txt_i="11437" txt_f="11992">] in another study reported the effect of Levamisole on the percentage of patients who found HB Antibody seroconversion but they did not explain the amount of antibody titers in detail. In our study only non-vaccinated stable hemodialysis patients were received Levamisole via ID or IM routs, but in the Kayatas study response rate of the pre-vaccinated patients via conventional rout was examined. The higher antibody response after ID vaccination could be due to more effector immune cells accessible in derm composed of Langerhans and dendritic cells [</offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="17950" xml_f="17952" txt_i="11992" txt_f="11994">27</offsets></xref><offsets xml_i="17959" xml_f="18101" txt_i="11994" txt_f="12136">]. The difference of immunomodulatory response to vaccination routs would be disappeared when Levamisole is added to the vaccination protocol.</offsets></p><p><offsets xml_i="18108" xml_f="18236" txt_i="12137" txt_f="12265">Quadruple injection protocol and addition of booster doses of vaccine when is necessary was suggested by Vlassopoulos DA etal. [</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="18268" xml_f="18270" txt_i="12265" txt_f="12267">28</offsets></xref><offsets xml_i="18277" xml_f="18973" txt_i="12267" txt_f="12963">]. But it is not cost effective for developing countries, such as us. Each dose of vaccine is approximately U.S.$ 3 but Levamisole has negligible price with minimal side effects if it be used for a short period of time such as 12 days as we used. The plasma elimination half-life of Levamisole is between 3–4 hours. Levamisole is extensively metabolized by the liver in humans and the metabolites excreted mainly by the kidneys (70% over 3 days). The elimination half-life of metabolite excretion is 16 hours. Approximately 5% is excreted in the feces. Less than 5% is excreted unchanged in the urine and less than 0.2% in the feces. The drug is not dialyzable, by hemo- or peritoneal membranes [</offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="19005" xml_f="19007" txt_i="12963" txt_f="12965">29</offsets></xref><offsets xml_i="19014" xml_f="19016" txt_i="12965" txt_f="12967">].</offsets></p><p><offsets xml_i="19023" xml_f="19302" txt_i="12968" txt_f="13247">The antibody production rate could be more stimulated by triggering of T helper cells, such as Levamisole or other immunomodulatory drugs. Levamisole can act either as immunostimulant depending upon dose administered the timing of its administration and host genetic background [</offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="19334" xml_f="19336" txt_i="13247" txt_f="13249">30</offsets></xref><offsets xml_i="19343" xml_f="19427" txt_i="13249" txt_f="13333">]. Levamisole also could induce an increase in the level of interleukin 2 receptor [</offsets><xref ref-type="bibr" rid="B31"><offsets xml_i="19459" xml_f="19461" txt_i="13333" txt_f="13335">31</offsets></xref><offsets xml_i="19468" xml_f="19537" txt_i="13335" txt_f="13404">] and T helper to T suppressor ratio in many dermatologic disorders [</offsets><xref ref-type="bibr" rid="B32"><offsets xml_i="19569" xml_f="19571" txt_i="13404" txt_f="13406">32</offsets></xref><offsets xml_i="19578" xml_f="19580" txt_i="13406" txt_f="13408">].</offsets></p><p><offsets xml_i="19587" xml_f="19830" txt_i="13409" txt_f="13652">We conclude that hemodialysis patients should be vaccinated perfectly by ID or IM route in addition of Levamisole. Future studies with larger number of patients are needed to validate our results as a routine protocol in hemodialysis patients.</offsets></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>The authors thank all dialysis patients and health workers in hemodialysis unit in Emam hospital of Tabriz, Iran. We also thank Dr. Taravat Ghafourian for her help about statistics.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Merat</surname><given-names>sh</given-names></name><name><surname>Malekzadeh</surname><given-names>R</given-names></name><name><surname>Rezvan</surname><given-names>H</given-names></name><name><surname>Khatibian</surname><given-names>M</given-names></name></person-group><article-title>Hepatitis B in Iran</article-title><source>Archives Iranian Medicine</source><year>2000</year><volume>3</volume><fpage>192</fpage><lpage>201</lpage></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shokrgozar</surname><given-names>MA</given-names></name><name><surname>Shokri</surname><given-names>F</given-names></name></person-group><article-title>HLA Associated anti body response to recombinant hepatitis B vaccine in lfean they Iranian adult</article-title><source>Iranian journal of medical science</source><year>1999</year><volume>3&amp;4</volume><fpage>85</fpage><lpage>103</lpage></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hassanjani</surname><given-names>MR</given-names></name><name><surname>Taheri</surname><given-names>H</given-names></name></person-group><article-title>Frequency of chronic active hepatitis in symptomatic HBV carriers in Babol, Iran</article-title><source>Archives of Iranian Medicine</source><year>2002</year><volume>5</volume><fpage>97</fpage><lpage>99</lpage></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rangel</surname><given-names>MC</given-names></name><name><surname>Coronado</surname><given-names>VG</given-names></name><name><surname>Euler</surname><given-names>GL</given-names></name><name><surname>Strikas</surname><given-names>RA</given-names></name></person-group><article-title>Vaccine recommendations for patients on chronic dialysis</article-title><source>seminars in dialysis</source><year>2000</year><volume>13</volume><fpage>101</fpage><lpage>07</lpage><pub-id pub-id-type="pmid">10795113</pub-id><pub-id pub-id-type="doi">10.1046/j.1525-139x.2000.00029.x</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chiuching</surname><given-names>H</given-names></name></person-group><article-title>Hepatitis infection in Hemodialyses patients</article-title><source>Nephrology</source><year>2002</year><volume>7</volume><fpage>101</fpage><lpage>09</lpage><pub-id pub-id-type="doi">10.1046/j.1440-1797.2002.00105.x</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>prospt</surname><given-names>T</given-names></name><name><surname>Prospt</surname><given-names>A</given-names></name><name><surname>Lhotta</surname><given-names>K</given-names></name><name><surname>Vogel</surname><given-names>W</given-names></name><name><surname>Konig</surname><given-names>P</given-names></name></person-group><article-title>Reinforced intradermal Hepatitis B vaccination in hemodialysis patient is superior in antibody response to intramuscular or subcutaneous vaccination</article-title><source>American Journal of kidney disease</source><year>1998</year><volume>32</volume><fpage>1041</fpage><lpage>45</lpage></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ayli</surname><given-names>D</given-names></name><name><surname>Ensari</surname><given-names>C</given-names></name><name><surname>Ayli</surname><given-names>M</given-names></name><name><surname>Mandiroglu</surname><given-names>F</given-names></name><name><surname>Mut</surname><given-names>S</given-names></name></person-group><article-title>Effect of oral Levamisole supplementation to hepatitis B vaccination on the rate of immune response in chronic hemodialysis patient</article-title><source>Nephron</source><year>2000</year><volume>84</volume><fpage>291</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">10720909</pub-id><pub-id pub-id-type="doi">10.1159/000045598</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sezer</surname><given-names>s</given-names></name><name><surname>Ozdemir</surname><given-names>FN</given-names></name><name><surname>Guz</surname><given-names>G</given-names></name><name><surname>Arat</surname><given-names>Z</given-names></name><name><surname>Colak</surname><given-names>T</given-names></name><name><surname>Sengul</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Factors influencing response to hepatitis B viruses vaccination in hemodialysis patients</article-title><source>Transplantation proceedings</source><year>2000</year><volume>32</volume><fpage>607</fpage><lpage>08</lpage><pub-id pub-id-type="pmid">10812136</pub-id><pub-id pub-id-type="doi">10.1016/S0041-1345(00)00914-3</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Irving</surname><given-names>WL</given-names></name><name><surname>Alder</surname><given-names>M</given-names></name><name><surname>Kurtz</surname><given-names>JB</given-names></name><name><surname>Juel- Jensen</surname><given-names>B</given-names></name></person-group><article-title>Intradermal vaccination against hepatitis B</article-title><source>Lancet</source><year>1986</year><volume>ii</volume><fpage>1340</fpage><pub-id pub-id-type="pmid">2878212</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(86)91474-1</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fabrizi</surname><given-names>F</given-names></name><name><surname>Lunghi</surname><given-names>G</given-names></name><name><surname>Poordad</surname><given-names>FF</given-names></name><name><surname>Martin</surname><given-names>P</given-names></name></person-group><article-title>Novel perspectives on hepatitis B vaccine in dialysis population</article-title><source>The international journal of Artificial organs</source><year>2002</year><volume>25</volume><fpage>172</fpage><lpage>81</lpage></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jafarzadeh</surname><given-names>A</given-names></name><name><surname>Shokrgozar</surname><given-names>MA</given-names></name><name><surname>Khoshnodi</surname><given-names>J</given-names></name><name><surname>Shokri</surname><given-names>F</given-names></name></person-group><article-title>Unresponsiveness to recombinant hepatitis B vaccine in healthy Iranian neonates: Association with HLA antigens</article-title><source>Iranian journal of medical science</source><year>2002</year><volume>27</volume><fpage>51</fpage><lpage>55</lpage></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Watkins</surname><given-names>SL</given-names></name><name><surname>Alexander</surname><given-names>SR</given-names></name><name><surname>Brewer</surname><given-names>ED</given-names></name><name><surname>Helsey</surname><given-names>TM</given-names></name><name><surname>West</surname><given-names>DJ</given-names></name><name><surname>Chan</surname><given-names>ISF</given-names></name><etal></etal></person-group><article-title>Response to recombinant hepatitis B vaccine in children and adolescents with chronic renal failure</article-title><source>American journal of kidney disease</source><year>2002</year><volume>40</volume><fpage>365</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1053/ajkd.2002.34521</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perez</surname><given-names>R</given-names></name><name><surname>Garcia</surname><given-names>AP</given-names></name><name><surname>Verbeelen</surname><given-names>D</given-names></name><name><surname>Bernstein</surname><given-names>ED</given-names></name><name><surname>Villarrubia</surname><given-names>VG</given-names></name><name><surname>Mon</surname><given-names>MA</given-names></name></person-group><article-title>AM3 (Immunoferon) as an adjuvant to hepatitis B vaccinationin Hemodialyses patients</article-title><source>Kidney international</source><year>2002</year><volume>61</volume><fpage>1845</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">11967036</pub-id><pub-id pub-id-type="doi">10.1046/j.1523-1755.2002.00335.x</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wistrom</surname><given-names>J</given-names></name><name><surname>Ahlm</surname><given-names>C</given-names></name><name><surname>Lundberg</surname><given-names>S</given-names></name><name><surname>Settergren</surname><given-names>B</given-names></name><name><surname>Tarnvik</surname><given-names>A</given-names></name></person-group><article-title>Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose</article-title><source>Vaccine</source><year>1999</year><volume>17</volume><fpage>2162</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">10367949</pub-id><pub-id pub-id-type="doi">10.1016/S0264-410X(99)00012-2</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramon</surname><given-names>JM</given-names></name><name><surname>Bou</surname><given-names>R</given-names></name><name><surname>Oromi</surname><given-names>J</given-names></name></person-group><article-title>Low dose intramuscular revaccination against hepatitis B</article-title><source>Vaccine</source><year>1996</year><volume>4</volume><fpage>1647</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">9032894</pub-id><pub-id pub-id-type="doi">10.1016/S0264-410X(96)00134-X</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pamela</surname><given-names>RW</given-names></name><name><surname>Kundi</surname><given-names>M</given-names></name><name><surname>Stemberger</surname><given-names>H</given-names></name><name><surname>Wiedermann</surname><given-names>G</given-names></name><name><surname>Holzmann</surname><given-names>H</given-names></name><name><surname>Hofer</surname><given-names>M</given-names></name><name><surname>Kollaritsch</surname><given-names>H</given-names></name></person-group><article-title></article-title><source>vaccine</source><year>2001</year><volume>19</volume><fpage>2055</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">11228377</pub-id><pub-id pub-id-type="doi">10.1016/S0264-410X(00)00410-2</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Slusarczyk</surname><given-names>Y</given-names></name></person-group><article-title>who needs vaccination on against hepatitis B Viruses</article-title><source>Vaccine</source><year>2002</year><volume>18</volume><fpage>54</fpage><lpage>55</lpage></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bonanni</surname><given-names>P</given-names></name></person-group><article-title>Universal hepatitis B immunization infant, and infant plus adolescent immunization</article-title><source>vaccine</source><year>1998</year><volume>16</volume><fpage>17</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(98)00286-2</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuff</surname><given-names>R</given-names></name></person-group><article-title>Imunogenicity of hepatitis B: implication of immune memory</article-title><source>Vaccine</source><year>2002</year><volume>20</volume><fpage>3695</fpage><lpage>3701</lpage><pub-id pub-id-type="pmid">12399197</pub-id><pub-id pub-id-type="doi">10.1016/S0264-410X(02)00405-X</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sammy</surname><given-names>S</given-names></name><name><surname>shiobhan</surname><given-names>RW</given-names></name><name><surname>Ly</surname><given-names>D</given-names></name><name><surname>brezina</surname><given-names>M</given-names></name><name><surname>Yee</surname><given-names>HF</given-names></name><name><surname>Han</surname><given-names>SH</given-names></name><name><surname>Gitnick</surname><given-names>G</given-names></name></person-group><article-title>Comparison of the cost and effectiveness of two strategies for maintaining hepatitis B immunity in hemodialysis patients</article-title><source>vaccine</source><year>2002</year><volume>20</volume><fpage>3230</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">12163275</pub-id><pub-id pub-id-type="doi">10.1016/S0264-410X(02)00249-9</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pyone kyi</surname><given-names>K</given-names></name><name><surname>May Oo</surname><given-names>K</given-names></name><name><surname>Moh Htun</surname><given-names>M</given-names></name><name><surname>Win Maw</surname><given-names>T</given-names></name><name><surname>Khin Khin</surname><given-names>A</given-names></name><name><surname>San San</surname><given-names>O</given-names></name><etal></etal></person-group><article-title>Clinical trial of the intradermal administration of hepatitis B vaccine produced at the department of medical research, Myanmar</article-title><source>vaccine</source><year>2002</year><volume>20</volume><fpage>1649</fpage><lpage>1652</lpage><pub-id pub-id-type="pmid">11858874</pub-id><pub-id pub-id-type="doi">10.1016/S0264-410X(01)00468-6</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arbizu</surname><given-names>EA</given-names></name><name><surname>Marugan</surname><given-names>R</given-names></name><name><surname>Grijalba</surname><given-names>JY</given-names></name><name><surname>Serrano</surname><given-names>PL</given-names></name><name><surname>Gilgrande</surname><given-names>L</given-names></name></person-group><article-title>Del campo terron S, Intramuscular versus intradermal administration of anti-hepatitis B vaccine in non cirrhotic hepatitis C patients</article-title><source>vaccine</source><year>2003</year><volume>21</volume><fpage>2747</fpage><lpage>2750</lpage><pub-id pub-id-type="pmid">12798613</pub-id><pub-id pub-id-type="doi">10.1016/S0264-410X(03)00221-4</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname><given-names>F</given-names></name><name><surname>Dahmen</surname><given-names>A</given-names></name><name><surname>Herzog-Hausff</surname><given-names>S</given-names></name><name><surname>Bocher</surname><given-names>Wo</given-names></name><name><surname>Galle</surname><given-names>PR</given-names></name><name><surname>Lohr</surname><given-names>HF</given-names></name></person-group><article-title>Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen</article-title><source>Hepatology</source><year>2000</year><volume>31</volume><fpage>521</fpage><lpage>527</lpage><pub-id pub-id-type="pmid">10655280</pub-id><pub-id pub-id-type="doi">10.1002/hep.510310237</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Platkov</surname><given-names>E</given-names></name><name><surname>Shlyakhof</surname><given-names>E</given-names></name><name><surname>Glick</surname><given-names>Y</given-names></name><name><surname>Khalemsky</surname><given-names>S</given-names></name><name><surname>Fischbein</surname><given-names>A</given-names></name></person-group><article-title>Immunologic evaluation of hepatitis B vaccine application in hospital staff</article-title><source>Int J occup Med Environ Health</source><year>2003</year><volume>16</volume><fpage>249</fpage><lpage>253</lpage><pub-id pub-id-type="pmid">14587538</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Hattum</surname><given-names>J</given-names></name><name><surname>Hepatitis</surname><given-names>B</given-names></name></person-group><article-title>vaccine: simple and effective</article-title><source>Ned Tijdschr Tandheelkd</source><year>1995</year><volume>102</volume><fpage>182</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">11837123</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kayatas</surname><given-names>M</given-names></name></person-group><article-title>Levamisole treatment enhances protective antibody response to hepatitis B vaccination in hemodialysis patients</article-title><source>Artif Organs</source><year>2002</year><volume>6</volume><fpage>492</fpage><lpage>496</lpage><pub-id pub-id-type="pmid">12072104</pub-id><pub-id pub-id-type="doi">10.1046/j.1525-1594.2002.06928.x</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hunsaker</surname><given-names>BD</given-names></name><name><surname>Perino</surname><given-names>L</given-names></name></person-group><article-title>Efficacy of intradermal vaccination</article-title><source>Veterinary Immunology and Immunopathology</source><year>2002</year><volume>79</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">11356246</pub-id><pub-id pub-id-type="doi">10.1016/S0165-2427(01)00244-6</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vlassopoulos</surname><given-names>DA</given-names></name><name><surname>Arvanitis</surname><given-names>DK</given-names></name><name><surname>Lilis</surname><given-names>DS</given-names></name><name><surname>Louizou</surname><given-names>KI</given-names></name><name><surname>Hadjiconstantinou</surname><given-names>VE</given-names></name></person-group><article-title>Lower long term efficiency of intradermal hepatitis B vaccine compared to the intramuscular route in hemodialysis patients</article-title><source>Int J Artif Organs</source><year>2000</year><volume>23</volume><fpage>282</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">10832664</pub-id></citation></ref><ref id="B29"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>CA</given-names></name><name><surname>Simmons</surname><given-names>WD</given-names></name></person-group><article-title>2002 Dialysis of Drugs</article-title><source>Nephrology Pharmacy Associates, Inc</source><year>2002</year><fpage>36</fpage></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Renoux</surname><given-names>G</given-names></name></person-group><article-title>The general immunopharmacology of Levamisole</article-title><source>Drugs</source><year>1980</year><volume>20</volume><fpage>89</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">6995097</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Obiri</surname><given-names>NI</given-names></name><name><surname>Dupere</surname><given-names>SL</given-names></name><name><surname>Pruett</surname><given-names>SB</given-names></name><name><surname>Lack-EY</surname><given-names>A</given-names></name><name><surname>Emma</surname><given-names>D</given-names></name><name><surname>O'Conner</surname><given-names>TE</given-names></name></person-group><article-title>Levamisole meets sulfhydryl requirments of CTLL/2 cells and mediates enhanced proliferative response to mitogen stimulation without increasing interleukin-2 production</article-title><source>J Biol Resopnse Mod</source><year>1990</year><volume>9</volume><fpage>288</fpage><lpage>299</lpage></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>A</given-names></name><name><surname>Chiang</surname><given-names>CP</given-names></name><name><surname>Chiou</surname><given-names>PS</given-names></name><name><surname>Wang</surname><given-names>JT</given-names></name><name><surname>Liu</surname><given-names>BY</given-names></name><name><surname>Wu</surname><given-names>YC</given-names></name></person-group><article-title>Immunomodulation by Levamisole in patients with recurrent aphthous ulcers or oral lichen planus</article-title><source>J Oral Pathol Med</source><year>1994</year><volume>23</volume><fpage>172</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">7913970</pub-id><pub-id pub-id-type="doi">10.1111/j.1600-0714.1994.tb01108.x</pub-id></citation></ref></ref-list></back></article>